MedPath

An explorative study to assess the changes in disease status in patients with systemic amyloidosis using amyloid PET/CT

Not Applicable
Recruiting
Conditions
Endocrine, nutritional and metabolic diseases
Registration Number
KCT0007077
Lead Sponsor
The Catholic University of Korea, Seoul St. Mary's Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
75
Inclusion Criteria

1) 19 years of age or older
2) In case of histological diagnosis of amyloidosis
3) If you voluntarily agree to participate in the study

Exclusion Criteria

1) In case of uncontrolled severe disease other than multiple myeloma
2) Decompensated heart failure inability to lie down immediately for 1 hour
3) Severe claustrophobia that does not improve even with the use of sedatives
4) Pregnant or lactating women
5) Serious liver disease
6) History of epilepsy

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
In patients with amyloidosis, dynamic changes in the degree of amyloid deposition are checked using amyloid PET/CT images before and after treatment.
Secondary Outcome Measures
NameTimeMethod
To evaluate the cardiac function of patients with amyloidosis and the degree of cardiac involvement on amyloid PET/CT.;Diagnosis of organ involvement in amyloid PET/CT in patients with amyloidosis, and evaluation of correlation with hematologic disease markers and other imaging test results.;To evaluate the association of amyloid PET/CT with haematological and affected organ responses after treatment of amyloidosis patients. To evaluate the potential of amyloid PET/CT as a therapeutic response evaluation tool.;To evaluate the potential of amyloid PET/CT as a predictive tool for post-treatment response and survival in patients with amyloidosis.;To evaluate the possibility of amyloid PET/CT as a tool to predict multiple myeloma-associated amyloidosis in patients with multiple myeloma.;To compare and evaluate the cognitive function test results of patients with amyloidosis and the degree of brain amyloid deposition on amyloid PET/CT.
© Copyright 2025. All Rights Reserved by MedPath